AIM ImmunoTech Inc. faces a June 11, 2026, deadline to regain compliance with NYSE American listing standards. The company must resolve specific deficiencies in its stockholders' equity to maintain its position on the exchange.
The NYSE American originally accepted the company’s remediation plan on February 26, 2025. This agreement followed an initial non-compliance warning issued to the firm in December 2024.
Failure to meet the minimum equity requirements by today's deadline could trigger the initiation of delisting proceedings. The outcome of this compliance review remains a pivotal event for the company’s stock and investor sentiment.